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PRECLINICAL STUDY
Novel Inhibitory Effect of Naloxone on
acrophage Activation and Atherosclerosis Formation in Mice
hu-Lin Liu, MS,*† Yi-Heng Li, MD, PHD,‡§ Guey-Yueh Shi, PHD,*‡ Yung-Huan Chen, MS,*
hia-Wei Huang, MS,*† Jau-Shyong Hong, PHD, Hua-Lin Wu, PHD*‡
ainan, Taiwan; and Research Triangle Park, North Carolina
OBJECTIVES We investigated whether naloxone could reduce macrophage activation and influence
atherosclerotic lesion formation in mice.
BACKGROUND Macrophages play an important role in the inflammatory process in atherosclerosis. Naloxone
could inhibit activation of microglia, the resident macrophage in the nervous system.
METHODS The anti-inflammatory effect of naloxone was evaluated by stimulating the macrophage cell
culture and FVB mice with lipopolysaccharide or oxidized low-density lipoprotein with and
without naloxone pretreatment. Apolipoprotein-E (apoE)-deficient mice received naloxone
injection for 10 weeks, and the severity of aortic atherosclerosis was measured. The left
common carotid arteries of C57BL/6 mice were ligated near the carotid bifurcation. The mice
then received naloxone injection for 4 weeks after ligation, and the severity of neointima
formation was evaluated.
RESULTS Naloxone pretreatment significantly suppressed the production of tumor necrosis factor-
(TNF-), interleukin-6, monocyte chemoattractant protein-1, and superoxide in macro-
phages after stimulation. In FVB mice, naloxone reduced the TNF- level in circulation,
inflammatory cell infiltration in lungs, and superoxide production in aorta. Naloxone injection
significantly decreased the severity of aortic atherosclerosis in the apoE-deficient mice and
carotid neointima formation in the C57BL/6 mice after ligation.
CONCLUSIONS Naloxone, with its novel anti-inflammatory effect, significantly reduces atherosclerosis and
neointima formation in mice. (J Am Coll Cardiol 2006;48:1871–9) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.036American College of Cardiology Foundation
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Mtherosclerosis remains a leading cause of morbidity and
ortality worldwide. Central to the pathogenesis of athero-
clerosis is the infiltration of monocytes/macrophages in the
rterial wall and the involvement of inflammation (1,2).
acrophages play a diverse array of roles in atherogenesis.
hey function as scavenger cells that takes up oxidized
ow-density lipoprotein (oxLDL) and become foam cells in
he initial lesion of atherosclerosis (3,4). After activation,
acrophages are capable of producing free radicals and
ro-inflammatory factors, all of which are critical for the
romotion of cellular proliferation and inflammation in
therosclerosis (3,4). Evidence indicates that atherosclerotic
esions could be decreased if monocyte/macrophage extrav-
sation and activation is inhibited (5,6). Naloxone is a
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ccepted July 3, 2006.on-selective antagonist of the opioid receptors that are
idely expressed not only in the central nervous system but
lso on the endothelium and monocytes (7,8). Previous
nimal studies found that naloxone can significantly de-
rease the inflammatory response in septic shock. Naloxone
mproves hypotension, leukocytosis, and prolonged survival
ime in endotoxin-induced shock rats (9,10). It inhibits the
roduction of tumor necrosis factor- (TNF-) induced by
ipopolysaccharide (LPS) in mice. Recent studies also show
hat naloxone reduces the pro-inflammatory factors and
uperoxide generation from LPS-induced microglia, the
esident macrophages within the nervous system (11,12).
ecause of the importance of macrophage-related inflam-
ation in the pathogenesis of atherosclerosis, we sought to
nvestigate the influence of naloxone on macrophage acti-
ation and determine the treatment effect of naloxone on
therosclerosis. In this study, we report that naloxone
reatment can reduce pro-inflammatory factors and super-
xide production in macrophage cell cultures and mice after
timulation. Naloxone injection might decrease the severity
f atherosclerotic lesion development in apolipoprotein-E
apoE)-deficient mice and the neointima formation in
ouse vascular remodeling model.
ETHODS
aterials. RPMI 1640 medium, phorbol 12-myristate-13-
cetate, LPS (Escherichia coli 0111:B4), and naloxone were
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uman acute monocytic leukemia cell line (THP-1) was
urchased from the Food Industry Research and Develop-
ent Institute (Hsin Chu, Taiwan). Levels of TNF-,
nterleukin-6 (IL-6), and monocyte chemoattractant
rotein-1 (MCP-1) in the medium or plasma were deter-
ined with monoclonal antibody-based enzyme-linked im-
unosorbent assay (ELISA) kits purchased from the R&D
ystems (Minneapolis, Minnesota). ApoE-deficient mice
ere obtained from the Jackson Laboratories (Bar Harbor,
aine). All animal experiments were approved by the
nstitutional Animal Care and Use Committee, National
heng Kung University.
ro-inflammatory factor and superoxide in THP-1 cell
ulture. The THP-1 cells were grown in the RPMI-1640
edium containing 10% fetal bovine serum at 37°C in 5%
arbon dioxide. The cells were differentiated to macro-
hages after treatment of the culture with 100 nmol/l
horbol 12-myristate-13-acetate for 24 h. The cell suspen-
ion (5 105) was added, 0.5 ml into each well of the tissue
ulture plates. For each experiment, naloxone was prepared
mmediately before use. The LPS was dissolved in sterile
ater and stored at 70°C in aliquots. The LDL was
solated from human endotoxin-free heparin plasma and
as oxidized with copper(II) sulphate (CuSO4) as described
reviously (13). In brief, LDL (1 ml, 1 mg/ml) was dialyzed
n 500 ml phosphate-buffered saline (PBS) (pH 7.4) over-
ight. Copper sulfate was added to a final concentration of
mol/l, and the LDL was allowed to oxidize at room
emperature for 24 h.
First, we examined the effective naloxone concentration
hat inhibited TNF- production from macrophages. Be-
ause a previous study (11) demonstrated that 1 mol/l
aloxone could protect neurons through inhibition of mi-
roglia activation, our initial experiment began with this
oncentration. The THP-1 cell culture was pretreated for
Abbreviations and Acronyms
apoE  apolipoprotein-E
DHE  dihydroethidium
EEL  external elastic lamina
ELISA  enzyme-linked immunosorbent assay
HDL  high-density lipoprotein
IEL  internal elastic lamina
IL-6  interleukin-6
LPS  lipopolysaccharide
MCP-1  monocyte chemoattractant protein-1
MTT  3 (4,5-dimethylthiazol-2-yl)
2, 5-diphenyltetrazolium bromide
NADPH  nicotinamide adenine dinucleotide phosphate
N/M  neointima/media area ratio
oxLDL  oxidized low-density lipoprotein
PBS  phosphate-buffered saline
RLU  relative light units
THP-1  human acute monocytic leukemia cell line
TNF-  tumor necrosis factor-h with various concentrations of naloxone (1 to 106 pmol/l) before treatment with 100 ng/ml LPS for 24 h. The
NF- level in the supernatant was determined by ELISA.
he most effective naloxone concentrations (1, 0.1, and 0.01
mol/l) were chosen for all the following experiments.
For study of pro-inflammatory factors, the THP-1 cell
ulture was pretreated for 1 h with naloxone (1, 0.1, or 0.01
mol/l) before treatment with 100 ng/ml LPS or 10 g/ml
xLDL for up to 24 h. The supernatants were harvested,
nd the TNF-, IL-6, and MCP-1 levels were determined
y ELISA. Superoxide production in the THP-1 cell
ulture was measured by lucigenin-enhanced chemilumines-
ence as described previously (14). The LPS-treated THP-1
ells were treated with PBS containing 1.25 mmol/l lucige-
in, and counts were obtained for a 10-min period in a
uminometer (Berthold Technologies, Germany) as rela-
ive light units (RLU) emitted. Background counts de-
ermined in cell-free preparations were subtracted. Su-
eroxide levels were reported as RLU/10 min and were
ormalized to the volume (ml) of cell suspension added
i.e., RUL/10 min/ml).
Cell viability was determined with the 3 (4,5-
imethylthiazol-2-yl) 2, 5-diphenyltetrazolium bromide
MTT) assay in each treatment group previously described.
riefly, fresh medium was added to cells together with 10%
TT (5 mg/ml). Each plate was maintained at 37°C for
h, and subsequently formazan crystals were dissolved in
imethylsulfoxide (DMSO). Absorbance was read at a
avelength of 550 nm with a SPECTRAmax PLUS384
pectrophotometer (Molecular Devices, Sunnyvale, Califor-
ia).
ro-inflammatory factor and superoxide production in
ice. The anti-inflammatory effect of naloxone in adult
ale FVB mice (8 to 12 weeks old) was examined. The mice
eceived pretreatment with intraperitoneal (IP) naloxone
10, 20, or 25 mg/kg) or PBS 30 min before the experiment.
ll mice then received 20 mg/kg LPS by IP injection. Blood
amples were obtained at 6 h after LPS injection from a
atheter placed in the left carotid artery. Blood samples were
entrifuged, and the plasma TNF- levels were measured by
LISA. Lungs were harvested from the animals 6 h after
PS injection in each group as previously described. The
issues were fixed in 4% paraformaldehyde and embedded in
araffin for histopathological examination. The presence of
nflammatory cells in lungs was determined by immunoflu-
rescence. The sections were incubated with rat monoclonal
ntibody against mouse CD45, a leukocyte common antigen
1:50 dilution; Pharmingen, San Diego, California). After
ashing, fluorescein isothiocyanate-conjugated sheep anti-
ouse immunoglobulin (Amersham Pharmacia Biotech,
iscataway, New Jersey) was applied as a secondary anti-
ody. A laser scanning confocal microscope (Leica Micro-
ystems, Wetzler, Germany) was used to examine the
amples, and the CD45-positive cells were demonstrated by
reen immunofluorescence labeling. The total CD45-
ositive cell number was counted in 5 randomly selected
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ach mouse.
Oxidative fluorescent microtopography with the oxidative
uorescent dye dihydroethidium (DHE) was used to evaluate
he in situ production of superoxide in aorta as described
reviously (15). Aortas were harvested from the animals at
h after LPS injection in each group as previously de-
cribed. Unfixed frozen ring segments were cut into 30-m-
hick sections and placed on a glass slide. The DHE (10
mol/l) was topically applied to each tissue section, and a
over slip was applied. Slides were incubated in a light-
rotected humidified chamber at 37°C for 30 min. Fluores-
ence was detected with a laser scanning confocal micro-
cope (Leica Microsystems) with excitation at 488 nm and
etection at 585 nm with a long-pass filter.
aloxone treatment in apoE-deficient mice. ApoE-
eficient mice were fed with a high cholesterol diet contain-
ng 21% fat and 0.15% cholesterol (PMI LabDiet 40097,
ichmond, Indiana) from 8 to 17 weeks of age. The apoE-
eficient mice received IP naloxone (10, 20, or 25 mg/kg/day)
r PBS injection for 10 weeks during this period. After
ompleting the treatment, blood samples were collected by
irect heart puncture when killing the animals. The serum
evels of total cholesterol, LDL, high-density lipoprotein
HDL), and triglycerides were measured by enzymatic
ethods with an automatic analyzer (Model 747, Hitachi
td. Co., Tokyo, Japan). The aorta was dissected from the
ortic valve to the iliac bifurcation. To identify lipid-rich
therosclerotic lesions, the aorta was rinsed in 50% isopro-
anol for 2 min, incubated in 0.67% Oil-Red-O for 15 min,
nd washed by 10% isopropanol for 2 min. With a dissec-
ion microscope, the area of each atherosclerotic lesion was
easured with Image Pro Plus software (Version 3.0.1;
edia Cybernetics, Inc., Silver Spring, Maryland) and
xpressed as percentage of atherosclerotic area / total area of
he aorta.
ffect of naloxone treatment in a mouse vascular remod-
ling model. Adult C57BL/6 mice (8 to 12 weeks) were
nesthetized by IP injection of sodium pentobarbital. The
eft common carotid artery was isolated and ligated com-
letely with a 6-0 silk suture near the carotid bifurcation as
escribed previously (16). The mice received IP naloxone
10, 20, or 25 mg/kg/day) or PBS injection for 4 weeks
mmediately after surgery. After completing the treatment,
he animals were killed and the segment of the left common
arotid artery just proximal to the ligation was excised, fixed
n 4% paraformaldehyde, and embedded in paraffin. Five
ransverse sections/animal were cut at 100-m intervals and
tained with hematoxylin-eosin. The borders of the internal
umen, internal elastic lamina (IEL), and external elastic
amina (EEL) were traced on a digitizing board with Meta
maging Series 5.0 software (Adobe Inc., San Jose, California).
he luminal, IEL, and EEL areas were measured. The
eointima area was calculated by subtracting the luminal
rea from the IEL area, and the media area was calculated
y subtracting the IEL area from the EEL area. The total Tascular area was represented by EEL area. The ratio of
eointima to media area (N/M ratio) was calculated. Aver-
ge values were obtained from morphometric analysis of
ach section of the animal.
tatistical analyses. Data were given as mean values  SD.
he Mann-Whitney U test was used to compare continuous
ariables between the 2 groups. Because there was a tre-
endous variability of vascular remodeling along the ligated
arotid artery and the distance to the ligation site might
nfluence the thickness of neointima formation, multiple
egression analysis was performed to simultaneously analyze
he contribution of the distance to ligation site and naloxone
reatment on the response of carotid ligation (17). All
tatistical analyses were performed with SPSS 12.0 (SPSS
nc., Chicago, Illinois). The statistical significance level was
et at p  0.05, 2-tailed.
ESULTS
ffect of naloxone on macrophage activation. The initial
xperiment demonstrated that the most effective naloxone
oncentration range was 0.01 to 1 mol/l. These concen-
rations could reduce TNF- production by 50% in the
HP1 cell culture after LPS stimulation (Table 1). Subse-
uent experiments were performed with these effective
aloxone concentrations. The LPS treatment induced a
ramatic increase of TNF- (8.02  0.42 ng/ml), IL-6
5.02  0.14 ng/ml), and MCP-1 (9.22  1.17 ng/ml) in
he medium of the THP-1 cell culture when compared with
he PBS treatment (TNF- 0.02  0.02 ng/ml, IL-6 0.03
.02 ng/ml, MCP-1 0.03  0.04 ng/ml). Naloxone pretreat-
ent (0.01, 0.1, and 1 mol/l) significantly reduced the
acrophage production of TNF- (0.01 mol/l, 4.28  0.39
g/ml; 0.1 mol/l, 4.10  0.37 ng/ml; 1 mol/l, 4.41 0.36
g/ml vs. 8.02 0.42 ng/ml, all p 0.05), IL-6 (0.01 mol/l,
.74 0.31 ng/ml; 0.1 mol/l, 3.28 0.14 ng/ml; 1 mol/l,
.44  0.48 ng/ml vs. 5.02  0.14 ng/ml, all p  0.05), and
CP-1 (0.01 mol/l, 7.08 0.16 ng/ml; 0.1 mol/l, 7.32
.33 ng/ml; 1 mol/l, 6.16 0.16 ng/ml vs. 9.22  1.17
able 1. Effect of Naloxone Pretreatment on Inhibition of
NF- Production From the THP-1 Cell Culture After LPS
timulation
Naloxone
retreatment (mol/l)
TNF- Production After
LPS (% control)
0 (control) 100  2
1 55  2*
101 51  6*
102 53  6*
103 67  3*
104 74  7†
105 93  4
106 90  10
esults are expressed as the percentage of the control group and are the mean
SD of 3 or 4 experiments. The value for control was 8.02  0.42 ng/ml. *p 
.01; †p  0.05 compared with the control group.
LPS  lipopolysaccharide; THP-1  human acute monocytic leukemia cell line;
NF-  tumor necrosis factor-.
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Naloxone Reduces Atherosclerosis Formation November 7, 2006:1871–9g/ml, all p  0.05) in the medium of THP-1 cells after
PS stimulation (Fig. 1).
After oxLDL stimulation, there was also a dramatic
ncrease of TNF- (1.70  0.06 ng/ml), IL-6 (1.51  0.08
g/ml), and MCP-1 (2.23  0.34 ng/ml) in the medium of
igure 1. Effect of naloxone treatment on the lipopolysaccharide (LPS)-
nduced macrophage release of tumor necrosis factor- (TNF-) (A),
nterleukin (IL)-6 (B), and monocyte chemoattractant protein (MCP)-1
C). Human acute monocytic leukemia cell (THP-1) culture was pretreated
or 1 h with the indicated concentrations of naloxone before stimulation
ith 100 ng/ml LPS. Supernatants were harvested at 24 h for the
easurement of TNF-, IL-6, and MCP-1. The results are expressed as
ean values  SD of 3 experiments. *p  0.05 compared with the
PS-treated cultures. PBS  phosphate-buffered saline.he THP-1 cell culture when compared with the PBS
o
Oreatment (TNF- 0.02  0.01 ng/ml, IL-6 0.01  0.01
g/ml, MCP-1 0.16 0.03 ng/ml). Naloxone pretreatment
0.01, 0.1, and 1 mol/l) significantly reduced the macro-
hage production of TNF- (0.01 mol/l, 0.85  0.12
g/ml; 0.1 mol/l, 0.62  0.04 ng/ml; 1 mol/l, 0.60 
.05 ng/ml; vs. 1.70 0.06 ng/ml, all p 0.05), IL-6 (0.01
mol/l, 1.05  0.03 ng/ml; 0.1 mol/l, 1.01  0.01 ng/ml;
igure 2. Effect of naloxone treatment on oxidized low-density lipoprotein
oxLDL)-induced macrophage release of TNF- (A), IL-6 (B), and
CP-1 (C). The THP-1 cell culture was pretreated for 1 h with the
ndicated concentrations of naloxone before stimulation with 10 g/ml
xLDL. Supernatants were harvested at 24 h for the measurement of
NF-, IL-6, and MCP-1. The results are expressed as mean values SD
f 3 experiments. *p  0.05 compared with the oxLDL-treated cultures.
ther abbreviations as in Figure 1.
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.05), and MCP-1 (0.01 mol/l, 0.95  0.28 ng/ml; 0.1
mol/l, 1.18 0.19 ng/ml; 1 mol/l, 1.09 0.24 ng/ml vs.
.23  0.34 ng/ml, all p  0.05) in the medium of THP-1
ells after oxLDL stimulation (Fig. 2).
Figure 3 shows the production of superoxide in the
HP-1 cell culture in the different treatment groups.
uperoxide production was significantly increased after LPS
timulation (817,000  90,000 RLU/10 min/ml) when
ompared with the control group treated with only PBS
183,000  39,000 RLU/10 min/ml). Naloxone pretreat-
ent (0.01, 0.1, and 1 mol/l) significantly suppressed the
levation of macrophage superoxide production (0.01
mol/l, 434,000  124,000 RLU/10 min/ml; 0.1 mol/l,
64,000  202,000 RLU/10 min/ml; 1 mol/l, 362,000 
4,000 RLU/10 min/ml vs. 817,000  90,000 RLU/10
in/ml, all p  0.05).
The MTT assays demonstrated that there were no
ignificant changes of the cell viability between the THP-1
ell cultures receiving PBS, LPS, 0.01, 0.1, or 1 mol/l
aloxone or LPS plus 0.01, 0.1, or 1 mol/l naloxone
retreatment.
ffect of naloxone on TNF- and superoxide production
n mice. Figure 4 shows the effect of naloxone on the
NF- and superoxide production in the mice after stim-
lation. The plasma level of TNF- was significantly
levated in the LPS-treated (n  9) compared with the
BS-treated (n  7) mice (576.1  43.6 pg/ml vs. 27.8 
3.1 pg/ml, p  0.001). Pretreatment of the mice with
aloxone (n  8 in 10 mg/kg, n  7 in 20 mg/kg, and n 
in 25 mg/kg naloxone) effectively reduced the elevation of
he plasma TNF- levels (10 mg/kg, 452.9  55.0 pg/ml,
 0.05; 20 mg/kg, 251.9  59.6 pg/ml, p  0.01; 25
g/kg, 288.0  33.9 pg/ml, p  0.01 vs. 576.1  43.6
igure 3. Effect of naloxone treatment on LPS-induced macrophage
roduction of superoxide. The THP-1 cell culture was pretreated for 1 h
ith the indicated concentrations of naloxone before stimulation with 100
g/ml LPS. Production of superoxide in THP-1 cell culture was measured
y lucigenin-enhanced chemiluminescence. Data are expressed as the mean
alues  SD of 3 experiments. *p  0.05 compared with the LPS-treated
ultures. RLU  relative light units; other abbreviations as in Figure 1.g/ml). There was more pulmonary inflammatory cell infil-
m
(ration in the mice after LPS stimulation (n  7) compared
ith PBS injection only (n  9; 103  16 vs. 45  10, p 
.01). In the mice pretreated with naloxone (n  5 in 10
g/kg, n  6 in 20 mg/kg, and n  5 in 25 mg/kg
aloxone), the infiltration of inflammatory cells in the lungs
as significantly decreased (10 mg/kg, 74  10; 20 mg/kg,
8  15; 25 mg/kg, 62  12, all p  0.01 vs. 103  16).
ortic sections from the mice were stained with DHE and
hen imaged with a laser scanning confocal microscope. The
PS-treated mice showed a marked increase in fluores-
ence, reflecting an increase in superoxide production in
orta (Fig. 5). Naloxone pretreatment (10, 20, and 25
g/kg) significantly reduced the increase of fluorescence
ntensity in the aortic sections from the LPS-treated mice.
igure 4. Effect of naloxone treatment on the plasma levels of TNF- (A)
nd the pulmonary inflammatory cell infiltration (B) in mice. (A) Mice
ere pretreated with the indicated dose of naloxone (n  8 in 10 mg/kg,
 7 in 20 mg/kg, and n  5 in 25 mg/kg naloxone) or PBS (n  7)
efore stimulation with LPS. Plasma TNF- levels were measured by
nzyme-linked immunosorbent assay. Data are expressed as mean values
D. *p 0.05; **p 0.01 compared with the LPS-treated only group (n 
). (B) Mice were pretreated with the indicated dose of naloxone (n  5 in
0 mg/kg, n  6 in 20 mg/kg, and n  5 in 25 mg/kg naloxone) or PBS
n  9) before stimulation with LPS. The presence of inflammatory cells
n lungs was determined by immunofluorescence. Data are expressed as theean values  SD. **p  0.01 compared with the LPS-treated only group
n  7). Other abbreviations as in Figure 1.
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Naloxone Reduces Atherosclerosis Formation November 7, 2006:1871–9ffect of naloxone on atherosclerosis and neointima
ormation. The apoE-deficient mice received IP naloxone
n  7 in 10 mg/kg, n  9 in 20 mg/kg, and n  8 in 25
igure 5. Superoxide formation in the mouse aorta evaluated by oxidative
uorescent microtopography with the oxidative fluorescent dye dihydro-
thidium (DHE). Representative photomicrographs of the aortic sections
n mice receiving lipopolysaccharide (LPS) (A), 20 mg/kg naloxone
retreatment 1 h before LPS (B), and phosphate-buffered saline (C) are
hown. Increased superoxide production was visualized by amplified red
uorescence in the aortic wall after LPS stimulation (A). In comparison,
taining was much more reduced in the aorta of animals receiving naloxone
retreatment (B) (bar  50 m).g/kg naloxone) or PBS (n  10) injection for 10 weeks.
o
1here were no significant differences of the total cholesterol,
riglyceride, LDL, and HDL levels between the PBS-
reatment and naloxone-treatment groups (Fig. 6). Nalox-
ne treatment for 10 weeks significantly reduced the severity
f aortic atherosclerotic lesions (10 mg/kg/day, 5.2  3.8%,
 0.01; 20 mg/kg/day, 3.4  1.4%, p  0.005; 25
g/kg/day, 1.8 1.2%, p 0.005 vs. PBS 12.9 6.1%) in
he apoE-deficient mice (Fig. 7).
There was a progressively decreased lumen area and
ncreased neointima formation in C57BL/6 mice after
arotid artery ligation (Fig. 8). The lumen area was signif-
cantly larger (10 mg/kg/day, 24,475  5,261 m2; 20
g/kg/day, 26,452  9,024 m2; 25 mg/kg/day, 29,650 
,643 m2, all p  0.05 vs. PBS 12,859  7,258 m2) at
igure 6. Influence of naloxone treatment on the plasma levels of choles-
erol (A), triglycerides (B), low-density lipoprotein (LDL) (C), and
igh-density lipoprotein (HDL) (D). Apolipoprotein-E–deficient mice
eceived an IP injection of 10 mg/kg/day (n  8), 20 mg/kg/day (n  7),
r 25 mg/kg/day (n 5) naloxone, or phosphate-buffered saline (n 8) for
0 weeks. The results are expressed as mean values  SD.
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 7 in 20, and n 5 in 25 mg/kg/day) compared with the
ontrol subjects receiving PBS only (n  7). The neointima
rea was significantly reduced (10 mg/kg/day, 20,052 
,372 m2, p  0.01; 20 mg/kg/day, 14,233  4,040 m2,
 0.005; 25 mg/kg/day, 13,865  3,494 m2, p  0.005
s. PBS 33,623  9,377 m2) after naloxone treatment.
he N/M ratio also decreased in the naloxone-treatment
roup (10 mg/kg/day, 0.66  0.15; 20 mg/kg/day, 0.41 
.18; 25 mg/kg/day, 0.39  0.07, all p  0.005 vs. PBS
.25  0.42) at 28 days after surgery (Fig. 8). In the
egression model (Table 2), naloxone treatment had a
tatistically significant influence on the lumen, neointima,
nd total vascular areas in carotid remodeling after ligation,
nd the effect was independent of the distance to ligation.
ISCUSSION
he present study is the first demonstration that naloxone
reatment can inhibit LPS-induced and oxLDL-induced
acrophage activation and decrease proinflammatory fac-
ors and superoxide production. We show that treatment
ith naloxone decreases the vascular lesion in apoE-
eficient mice and the neointima formation in C57BL/6
igure 7. Influence of naloxone treatment on atherosclerotic lesion forma-
ion in apolipoprotein-E (apoE)-deficient mice (A). The lipid-rich athero-
clerotic lesions were identified with Oil-Red-O staining. Lesion area (%)
as expressed as percentage of atherosclerotic area/total area of the aorta
B). The apoE-deficient mice received an IP injection of phosphate-
uffered saline (PBS) (n  8), 10 mg/kg/day (n  8), 20 mg/kg/day (n 
), or 25 mg/kg/day (n  5) naloxone for 10 weeks. The results are
xpressed as mean values  SD. **p  0.01; ***p  0.005 compared with
he control substance.ice receiving carotid artery ligation.
r
1nti-inflammatory effect of naloxone. It has been re-
orted that the opioid receptor antagonists naloxone and
altrexone display a novel anti-inflammatory effect. Recent
tudies demonstrated that naltrexone protects mice from
eptic shock induced by LPS (18,19). The compound
uppresses plasma TNF- elevation and reduces superoxide
roduction in the aorta (18,19). Naloxone treatment inhib-
ts the activation of microglia, the resident macrophage in
rain, and its production of TNF-, IL-1beta, and super-
xide (11,12,20). Naloxone also can decrease cerebral isch-
mic injury by reducing neutrophil accumulation and che-
okine expression (21). However, the mechanisms of
aloxone’s anti-inflammatory effect have not been fully
lucidated. The protective effect might not be directly
elated to opioid receptor binding, because the naloxone
tereoisomer ()-naloxone, an ineffective opioid receptor
ntagonist, also shows a similar anti-inflammatory effect
22). Recent evidence indicates that microglial nicotinamide
igure 8. (A) Representative photomicrographs of hematoxylin-eosin
taining of arterial sections 28 days after carotid ligation in mice receiving
aloxone (right panel) or phosphate-buffered saline (PBS) injection (left
anel). Arrows indicate borders of the neointima and media. Original
agnification 200. (B) Morphometric analysis of the lumen, neointima,
edia, and total vascular areas. Values are mean SD of 5 sections in each
ouse. *p  0.05; **p  0.01; ***p  0.005 compared with the mice
eceiving PBS injection. (C) Degree of neointima formation 28 days after
arotid ligation was calculated according to neointima/media area (N/M)
atio. ***p 0.005 compared with the mice receiving PBS injection (bar
00 m).
a
b
h
s
p
m
o
e
a
e
W
a
r
m
d
p
a
N
T
t
(
h
l
s
m
s
e
c
N
d
t
r
W
r
n
1
c
t
d
h
r
e
l
s
a
s
d
i
d
a
t
a
e
b
s
(
m
i
i
m
m
l
t
4
n
T
b
w
N
T
M
L
N
M
T
L
N
M
T
L
N
M
T
A
1878 Liu et al. JACC Vol. 48, No. 9, 2006
Naloxone Reduces Atherosclerosis Formation November 7, 2006:1871–9denine dinucleotide phosphate (NADPH) oxidase might
e a target of naloxone action. Microglial NADPH oxidase
as been shown to be responsible for the production of
uperoxide that is toxic to neurons and amplified microglial
roinflammatory gene expression (23). The naloxone-
ediated anti-inflammatory effect disappeared in NADPH
xidase-deficient mice, indicating that inhibition of this
nzyme is critical to the protective mechanism of naloxone
nd its related compound (23–25). Our study results further
xtend the previous observation of naloxone in microglia.
e found that naloxone could inhibit the macrophage
ctivation after LPS and oxLDL stimulation. Naloxone
educed the TNF- production up to 50% (Figs. 1 and 2) in
able 2. Regression Model of Carotid Ligation Response in
ice Receiving Naloxone or Saline Treatment
Naloxone
(10 mg/kg/day) Distance to Ligation
umen area
Coefficient 12,016 1,806
p value 0.001 0.857
eointima area
Coefficient 13,951 4,628
p value 0.001 0.657
edia area
Coefficient 2,950 4,288
p value 0.176 0.574
otal area
Coefficient 11,000 8,916
p value 0.007 0.519
Naloxone
(20 mg/kg/day) Distance to Ligation
umen area
Coefficient 14,033 12,073
p value 0.001 0.276
eointima area
Coefficient 19,584 21,986
p value 0.001 0.023
edia area
Coefficient 10,001 4,685
p value 0.001 0.645
otal area
Coefficient 9,582 26,672
p value 0.012 0.046
Naloxone
(25 mg/kg/day) Distance to Ligation
umen area
Coefficient 16,993 20,041
p value 0.001 0.06
eointima area
Coefficient 20,380 5,073
p value 0.001 0.619
edia area
Coefficient 8,112 30,696
p value 0.015 0.009
otal area
Coefficient 12,267 35,770
p value 0.01 0.033
rea  B1  B2 naloxone  B3 distance mm.acrophage after LPS and oxLDL stimulation. It also decreased the superoxide production about 40% in macro-
hage stimulated by LPS (Fig 3). These results are in
ccordance with the previous report that microglia from
ADPH oxidase-deficient mice display a 50% reduction in
NF- messenger ribonucleic acid expression in response
o LPS stimulation and are unable to produce superoxide
23). The superoxide derived from NADPH oxidase en-
ances the pro-inflammatory gene expression (26). It is
ikely that naloxone blocks the NADPH oxidase-dependent
uperoxide production, accounting for the 50% reduction of
acrophage TNF- production after stimulation. Further
tudies with opioid receptor knockout mice are necessary to
lucidate the naloxone anti-inflammatory mechanism more
learly.
aloxone and atherosclerosis. We used the apoE-
eficient mice and vascular remodeling murine models to
est the hypothesis that naloxone could decrease atheroscle-
osis through its inhibitory effect on macrophage activation.
e started from the naloxone dose (10 mg/kg) that rescues
ats or mice from septic shock (18,19). The 10 to 25 mg/kg
aloxone doses were approximately equivalent to about
03 to 104 mol/l blood concentrations in mice. These
oncentrations were effective in reducing TNF- produc-
ion from macrophage (Table 1). The apoE-deficient mice
evelop lesions that have many of the histological features of
uman atherosclerosis, including lipid deposition and mac-
ophage infiltration (27,28). Monocytes attachment to the
ndothelium could be observed at 6 weeks, and foam cell
esions could be developed as early as 8 weeks of age. In our
tudy, naloxone treatment that was started from 8 weeks of
ge in the apoE-deficient mice significantly attenuated the
everity of atherosclerotic lesion formation. Our results
emonstrate that naloxone inhibits macrophage activation
n an early stage and the severity of atherosclerosis lesion
ecreases. In the vascular remodeling model, because the
rterial pulsation is still present, there is only minimal
hrombus formation near the ligation site (16,29). The
ltered flow condition after ligation not only increases the
xpression of endothelial-leukocyte adhesion molecules
ut also leads to the monocytes activation, with a
ubsequent influx of monocytes into the vessel wall
16,30,31). Although there is no lipid component in this
odel, flow cessation produces significant vessel wall
nflammation and causes a smooth muscle cell-rich neo-
ntima. A previous study supported an important role of
acrophage infiltration in the up-regulation of matrix
etalloproteinase and vascular smooth muscle cell pro-
iferation in the arterial remodeling process and neoin-
ima formation (32). In our study, naloxone treatment for
weeks after carotid ligation could reduce the severity of
eointima formation and alter the remodeling process.
his effect might have important clinical implications,
ecause the major source of oxidative stress in the artery
all is the monocyte/macrophage NADPH oxidase (33).
aloxone blockage of macrophage activation with re-uced oxidative stress and inflammation in the vascula-
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November 7, 2006:1871–9 Naloxone Reduces Atherosclerosis Formationure is likely to prevent the deterioration of atheroscle-
osis or neointima formation. Further studies are required
o determine the effect of naloxone on vascular disease
nd restenosis in humans. For statistical analyses in the
tudy, although there were many individual comparisons
ithin studies, the statistical tests were performed ac-
ording to the hypotheses that were determined before
he experiment. So the multiple comparisons should not
e a major concern.
On the basis of these observations, we propose that
aloxone can inhibit macrophage activation after LPS and
xLDL stimulation with reduced oxidative stress. It can
erve as a protective anti-oxidative and anti-inflammatory
gent in the prevention of atherosclerotic plaque and neo-
ntima formation in the vascular system.
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